HC Wainwright Reaffirms “Buy” Rating for Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $37.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 321.89% from the stock’s previous close.

Separately, Jefferies Financial Group started coverage on Pharming Group in a research report on Monday, December 9th. They set a “buy” rating and a $14.00 price target on the stock.

Pharming Group Stock Up 0.3 %

Shares of PHAR stock opened at $8.77 on Friday. The stock’s 50-day simple moving average is $8.99 and its 200-day simple moving average is $8.58. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The firm has a market capitalization of $596.63 million, a PE ratio of -33.73 and a beta of -0.10. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $11.80.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The company had revenue of $92.70 million during the quarter, compared to analysts’ expectations of $76.67 million. Equities analysts expect that Pharming Group will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group (NASDAQ:PHAR) by 16.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.